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MaOBJECTIVES This study sought to evaluate the feasibility of the CGuard Carotid Embolic Protective Stent system—a
novel thin strut nitinol stent combined with a polyethylene terephthalate mesh covering designed to prevent embolic
events from the target lesion in the treatment of carotid artery lesions in consecutive patients suitable for carotid
artery stenting.
BACKGROUND The risk of cerebral embolization persists throughout the carotid artery stenting procedure and remains
during the stent healing period.
METHODS A total of 30 consecutive patients (age 71.6  7.6 years, 63% male) meeting the conventional carotid artery
stenting inclusion criteria were enrolled in 4 centers in Germany and Poland.
RESULTS The primary combined endpoint was the procedure success of the CGuard system and the number and volume
of new lesions on the ipsilateral side assessed by diffusion-weighted magnetic resonance imaging at 48 h post-procedure
and at 30 days. The secondary endpoint was 30-day major adverse cardiac or cerebrovascular events (death, stroke,
or myocardial infarction). Protection devices were used in all procedures. Procedure success was 100%, with 0%
procedural complications. The 30-day major adverse cardiac or cerebrovascular events rate was 0%. New ipsilateral
ischemic lesions at 48 h occurred in 37.0% of patients and the average lesion volume was 0.039  0.08 cm3. The 30-day
diffusion-weighted magnetic resonance imaging showed complete resolution of all but 1 periprocedural lesion and
only 1 new minor (0.116 cm3) lesion in relation to the 48-h scan.
CONCLUSIONS The use of the CGuard system in patients undergoing carotid artery stenting is feasible. In addition,
the beneﬁt of using CGuard may extend throughout the stent healing period. (J Am Coll Cardiol Intv 2015;8:1229–34)
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ABBR EV I A T I ON S
AND ACRONYMS
CAS = carotid artery stenting
DW-MRI = diffusion-weighted
magnetic resonance imaging
MACCE = major adverse
cardiac or cerebrovascular
event(s)
TIMI = Thrombolysis In
Myocardial Infarction
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1230C arotid artery stenting (CAS) is asso-ciated with a stroke risk mainlydue to dislodgement of debris from
the target lesion during the procedure. The
CGuard Embolic Protection Stent (InspireMD
Inc., Boston, Maryland) is a novel thin strut
nitinol stent combined with a polyethylene
terephthalate mesh covering designed to
trap and exclude thrombus and friable ather-
omatous debris to prevent acute and lateembolic events from the target lesion. The CARENET
(Carotid Embolic Protection Using MicroNet) trial was
the ﬁrst multicenter study of CGuard following the CE
Mark of this device in March 2014. The trial was
designed to evaluate the feasibility of the CGuard sys-
tem in the treatment of carotid lesions and the num-
ber and volume of new lesions on the ipsilateral side
assessed by diffusion-weighted magnetic resonance
imaging (DW-MRI) at 48 h post-procedure and at
30 days in consecutive patients suitable for CAS in a
multioperator, real-life setting.SEE PAGE 1235METHODS
STUDY DESIGN AND PATIENTS. The prospective
multicenter single arm clinical trial included 30
consecutive eligible patients enrolled in 4 centers in
Germany and Poland. The principal inclusion criteria
were age of at least 18 years, written informed con-
sent, de novo atherosclerotic target lesion. Symp-
tomatic patients had to have transient ischemic
attack, stroke, or amaurosis fugax within the last
6 months on the ipsilateral side with carotid
stenosis $50% as diagnosed by angiography using
NASCET (North American Symptomatic Carotid End-
arterectomy Trial) criteria. Asymptomatic subjects
had to have carotid stenosis $80% that qualiﬁed
for revascularization in the opinion of a vascular
specialist and an independent neurologist. The prin-
cipal exclusion criteria were stage III renal insufﬁ-
ciency, acute stroke within 30 days, myocardial
infarct within 72 h, atrial ﬁbrillation, or any other
than carotid stenosis known reason for stroke, total
occlusion of the index carotid artery, a pre-existing
stent that extended into the aortic arch, severe cir-
cular calciﬁcation of the target lesion, and lesion
length exceeding 30 mm.
CAS PROCEDURE. The CAS procedure was to follow
the operator’s routine except for the use of CGuard in
place of a conventional noncovered carotid stent. In
particular, the vascular access and the type of embolic
protection during CAS were left to the discretion ofthe operator. Because CAS-related embolization is not
limited to the stent deployment and post-dilation
phase (1), use of an embolic protection device was
recommended.
DEVICE DESCRIPTION. The CGuard System is a carotid
stent wrapped with a MicroNet mesh, mounted on
a self-expandable delivery system compatible with a
6-F (2.0-mm) catheter (Figure 1). The pore size of
the mesh when the stent is fully expanded is 150 to
180 mm. Prior to carotid application, this particular
mesh type was evaluated in the coronary balloon–
expandable stents where it demonstrated a substan-
tial beneﬁt in myocardial perfusion, indicating its
impact on reducing thrombotic lesion embolization
(2). The CGuard System is available in an array of
diameters (6 to 10 mm) and lengths (20 to 60 mm),
and is CE-marked for this indication.
STUDY ENDPOINTS AND DEFINITIONS. The primary
combined endpoint was the procedure success of the
CGuard system and the number and volume of new
lesions on the ipsilateral side assessed by DW-MRI at
48 h post-procedure and at 30 days. Procedure suc-
cess was deﬁned as device delivered to the target
lesion, deployed in the target lesion, and delivery
system retrieved. Secondary endpoints were 30-day
major adverse cardiac or cerebrovascular events
(MACCE) (death, stroke, or myocardial infarction), in-
hospital MACCE, and any procedural complications.
Per-protocol analysis also includes 12-month MACCE;
ipsilateral stroke from 31 days to 1 year; peak systolic
velocity and end-diastolic velocity assessment at
30 days, 6 months, and 12 months. Diameter stenosis
was determined angiographically according to the
NASCET criteria (3). The ﬂow in the external carotid
artery was determined according to modiﬁed TIMI
(Thrombolysis In Myocardial Infarction) criteria (4).
Perfusion was deﬁned as follows: TIMI ﬂow grade
0 ¼ no ﬂow; TIMI ﬂow grade 1 ¼ penetration without
perfusion; TIMI ﬂow grade 2 ¼ partial perfusion;
TIMI ﬂow grade 3 ¼ complete perfusion.
Detailed evaluation of the patient status at base-
line, 24 h after CAS, and at 30 days was by a consul-
tant neurologist independent of the study team.
Angiographic and DW-MRI analysis were performed
by external core labs, independent of the study
sponsor or investigators.
DW-MRI ANALYSIS. MR images available for analysis
included T1, T2, ﬂuid attenuated inversion recovery,
DW-MRI, and apparent diffusion coefﬁcient se-
quences. The images were evaluated by a core lab
neuroradiologist without the knowledge of the pa-
tient’s age, sex, or symptoms. Images were analyzed
TABLE 1 Baseline and Procedural Characteristics (N ¼ 30)
Age, yrs 71.6  7.6
Male 63.4
Hypertension 83.3 (25)
Hyperlipidemia 90 (27)
Diabetes mellitus 23.3 (7)
Cigarette smoking, current 13.4 (4)
Previous myocardial infarction 26.7 (8)
Previous TIA 13.3 (4)
NIH stroke scale 1.37  2.6
Femoral access 100 (30)
Target vessel
Left ICA 33.3 (10)
Right ICA 66.6 (20)
Protection used
Distal ﬁlter protection 96.6 (29)
Proximal balloon protection 3.4 (1)
Pre-dilation 70.9 (22)
Post-dilation 77.4 (24)
Post-dilation pressure, atm 13.6  4.5
Procedure success 100 (30)
Stent deployed 100 (30)
Stent diameter, mm 8.23  0.8
Stent length, mm 34.8  5.0
Second stent used 3.33 (1)
Values are mean  SD, %, or % (n).
ICA¼ internal carotid artery; NIH¼ National Institutes of Health; TIA¼ transient
ischemic attack.
FIGURE 1 CGuard System
The CGuard System is a carotid stent wrapped with MicroNet
mesh, mounted on a self-expandable delivery system. The
CGuard System is CE-marked and is available in an array of
diameters (6 to 10 mm) and lengths (20 to 60 mm).
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1231for evidence of acute ischemia as indicated by sig-
niﬁcant restricted diffusion (increased signal) with
corresponding decreased apparent diffusion coefﬁ-
cient and no or minimal T2/ﬂuid attenuated inversion
recovery signal.
Volume analysis of acute ischemic lesions was
measured on a separate workstation (Olea Medical,
La Ciotat, France) using a region-growing image
segmentation technique.
RESULTS
PATIENT CHARACTERISTICS AND PROCEDURAL
DETAILS. Consistent with the study protocol, 30
consecutive, all-comer patients were enrolled at 4
sites in Europe. Full baseline and procedural charac-
teristics are summarized in Table 1. Mean age was
71.6 years and 63% of patients were male. Among the
major risk factors, 23% patients had diabetes and 27%
had previous MI. Ten patients (33.3%) had symptom-
atic carotid artery stenosis. Distal ﬁlter protection
devices were used in 29 patients (Emboshield [Abbott
Vascular, Temecula, California] in 8 patients; EPI ﬁlter
wire [Boston Scientiﬁc, Marlborough, Massachusetts]
in 11 patients; and Spider FX [eV3, Plymouth, Minne-
sota] in 10 patients) and proximal balloon protection
(MoMa [Medtronic, Minneapolis, Minnesota]) in 1 pa-
tient. Pre-dilation was performed in 70.9% of the
cases and post-dilation in 77.4%. The CGuard System
was delivered and deployed in all cases (procedural
success 100%).
ANGIOGRAPHIC RESULTS. The index lesion was
located in the left internal carotid artery in 33.3% and
in the right in 66.6% of patients. The average length
and reference vessel diameter were 16.94  4.7 mmand 6.18  0.68 mm, respectively. Mean percentage
of diameter stenosis was 79.9  5.0, which decreased
to 16.9  6.5 post-intervention. The complete angio-
graphic data is shown in Table 2.
CLINICAL OUTCOMES AT 30 DAYS. Clinical follow-
up at 30 days was available in all 30 patients.
MACCE was 0%.
DW-MRI OUTCOMES AT 48 H AND 30 DAYS.
DW-MRI imaging analysis was available for 28 pa-
tients at baseline (the analysis of 2 patients was not
feasible due to multiple dental work artifacts and a
large recent cerebral artery ischemia on the baseline
scan precluding analysis of any potential new lesions
in the context of CAS); for 27 patients at 48 h (1 MRI
was not done in the study window) and for 26
patients at 30 days (2 patients without any lesions
on the baseline and 48-h scans and who were free
of symptoms did not agree to the 30-day scan).
At baseline, 2 patients showed minor DW-MRI
lesions (total of 12 lesions, average volume of 0.06 
0.27 cm3). At 48 h after the stent procedure, DW-MRI
analysis revealed that 10 of 27 patients (37.0%) had
new acute ischemic lesions on the ipsilateral side
with a total of 83 lesions, driven mostly by a single
patient in whom proximal protection was used, with
TABLE 3
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Average le
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TABLE 2 Angiographic Results
Baseline Final
Lesion location in left/right ICA 33 left/67 right —
Lesion length, mm 16.94  4.7 —
RVD, mm 6.18  0.68 —
MLD, mm 1.25  0.34 4.82  0.60
Percentage of in-stent diameter stenosis 79.9  5.0 16.9  6.5
TIMI ﬂow grade 3 in the ECA 100.0 100.0
Values are % or mean  SD. Dashes indicate that data are not available.
ECA ¼ external carotid artery; ICA ¼ internal carotid artery; MLD ¼ minimal lumen diameter;
RVD ¼ reference vessel diameter; TIMI ¼ Thrombolysis In Myocardial Infarction.
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123254 new lesions. The average lesion volume was
0.039  0.08 cm3. Six patients (22.2%) had new
contralateral lesions. The total number of contralat-
eral lesions was 34, with average lesion volume was
0.03  0.08 cm3 (range 0.028 to 0.325 cm3). Twelve
study subjects (46.2%) showed new bilateral lesions
48 h after CAS. The average lesion volume was
0.05  0.09 cm3.
All but 1 new ipsilateral lesion at 48 h had resolved
by 30 days. DW-MRI at 30 days showed only 1 new
ipsilateral lesion (4.0%, 0.116 cm3) without any new
lesions on the contralateral side. Key DW-MRI data
are presented in Table 3.DISCUSSION
The principal ﬁndings from the present study are the
following:
1. Procedure success rate was 100% with no
compromise of blood ﬂow in the external carotid
artery.New Ipsilateral Lesions by DW-MRI Analysis*
48 H
n ¼ 27
30 Days
n ¼ 26
ith new AIL 10 1
of new lesions, % 37.0 4.0
ber of new AIL 83† 1
umber of new AIL per patient‡ 3.19  10.33 0.04  0.20
sion volume, cm3 0.039  0.08 0.08  0.00
lesion volume, cm3 0.445 0.116
t AIL at 30 days — 1
ounts or mean  SD. *At baseline, 1 patient had signiﬁcant MRI artifacts from a dental
t disabled cerebral analysis. DW-MRI in another subject demonstrated middle cerebral
mia whose extent was prohibitive for an analysis of any further lesions in relation to
b exclusion). At 48 h, 1 patient did not have an MRI, but did have one at baseline and
o additional patients did not agree to the 30-day MRI scan. †One patient had 54 new
the 48-h scan. ‡For 48-h imaging in relation to the pre-CAS (baseline) scan; new
0 days are in relation to the scan at 48 h after CAS.
ute ischemic lesions; CAS ¼ carotid artery stenting; DW-MRI ¼ diffusion-weighted
sonance imaging; MRI ¼ magnetic resonance imaging.2. The new ipsilateral DW-MRI lesions present at 48 h
in 37% of study patients were minor and all but 1
lesion resolved completely by 30 days, and the
majority of the patients (63.0%) did not have
any new procedure-related acute ischemic lesions
at 48 h.
3. The 30-day MACCE rate was 0% in symptomatic
as well as asymptomatic patients undergoing
CAS with a novel mesh-covered carotid stent.
CAS has emerged as an alternative to carotid
endarterectomy (5–10). CAS is associated with risk
of embolization at every step of the procedure,
including cannulation of the target artery, place-
ment of the guiding catheter/sheath, wiring of the
lesion, pre-dilation, stent placement and release,
and stent post-dilation (1). Although current data
support the use of embolic protection devices for
CAS (11), embolic protection devices do not cover all
the emboli-generating CAS phases. With conven-
tional carotid stents, the most emboli-generating
CAS phases are stent deployment and post-dilation
(1). In a substudy of the SPACE (Stent-Supported
Percutaneous Angioplasty of the Carotid Artery
versus Endarterectomy) trial, the event rate was
higher in the group of patients who received an
open cell versus a closed cell stent (12). Also Schnau-
digel et al. (13) found a signiﬁcantly higher incidence
of new ipsilateral DW-MRI lesions in patients who
received an open versus a closed carotid stent.
Therefore, tailored CAS algorithms have been pro-
posed that include conventional carotid stent type
selection based on the lesion morphology and target
vessel anatomy (14) or maximized use of proximal
neuroprotection (15). Plaque protrusion through the
stent struts may provide a mechanism for emboliza-
tion not only during CAS (when this risk may be
minimized by embolic protection) but also following
the CAS procedure. Indeed, De Donato et al. (16) per-
formed optical coherence tomography after carotid
stenting and found plaque prolapse related to the
design of implanted stents in up to 68.6% of patients
(for open cell stents).
In line with these ﬁndings, in an earlier DW-MRI
study, we could demonstrate that cerebral emboliza-
tion after CAS is an ongoing process beyond the time
of the procedure in a signiﬁcant number of patients
(17). In another study using conventional carotid
stents, up to two-thirds of CAS-associated adverse
neurological events occurred after the procedure,
within the stent healing period of about 30 days (18).
This explains why temporary brain protection sys-
tems are ineffective in abolishing CAS-associated
adverse neurological events. Detailed analysis of
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1233data, generated using an open-cell stent suggest
that prevention of plaque and thrombotic material
protrusion through the struts may result in reduced
CAS-associated embolization (10,18,19).
CGuard is a nitinol self-expanding stent covered
by MicroNet mesh with a pore size ranging from 150
to 180 mm, which prohibit cerebral embolization but
allow for unimpeded ﬂow to the external carotid ar-
tery in case of bifurcation stenting. This embolic
protection stent system, aimed to reduce the risk of
early and late cerebral embolization, was tested in
the present CARENET study in an all-comer patient
population with carotid stenosis referred for revas-
cularization. Our multicenter study demonstrates
that CGuard is compatible with all embolic protection
device types used in an all-comer patient population.
The stent could be successfully implanted in all
patients with a MACCE rate of 0% and TIMI ﬂow grade
3 to the external carotid artery.
DW-MRI is a sensitive tool in identifying cerebral
emboli during CAS (20). In the present study, 37.0%
of patients had new ischemic lesions with an
average volume of lesions per patient of 0.039 cm3.
This compares very favorably with data from the
PROFI (Prevention of Cerebral Embolization by
Proximal Balloon Occlusion Compared to Filter
Protection During Carotid Artery Stenting) trial (15)
as well as the MRI substudy of the ICSS (Interna-
tional Carotid Stenting Study) (8), where the in-
cidences of new ipsilateral lesions were 66.2%
(average of both proximal and distal ﬁlter groups)
and 68.0% (ipsilateral and bilateral lesions com-
bined), respectively, and average lesion volume
0.375 cm3.
Studies of DW-MRI after emboli-protected CAS
have consistently reported a paucity of overt neuro-
logical complications in the presence of focal
ischemic brain injury (11,21,22). In a previous study
(20), we found that patients with post-CAS brain
ischemia who sustained a major stroke had both a
markedly higher number of ischemic foci and a larger
area covered by an ischemic focus than did patients
without neurological symptoms. These ﬁndings of an
association between the cerebral embolic load and
adverse neurologic events were recently supported
by Kastrup et al. (11) and are consistent with recent
data from the ICSS study (23). The present study has
found not only a low incidence and cerebral lesion
number on DW-MRI using the CGuard system, but
also a small size of the limited embolic lesions that
did occur.
Little is known about the extent by which focal
cerebral ischemia affects cognitive function. In arecent study (24), a deterioration of cognitive
function after emboli-protected CAS was observed
at discharge in 18 of 22 patients with cerebral
ischemia on post-CAS DW-MRI. A decline in cogni-
tive function has also been found in elderly patients
with silent brain infarcts (25). The best CAS proce-
dure is the one with optimal angiographic result
paralleled by minimal embolization both during
procedure and afterward, during stent healing.
Thus, minimization of new ischemic lesions during
and after CAS using the CGuard system is antici-
pated to translate into clinical beneﬁt for the pa-
tients treated with a mesh-covered embolic
protection stent.
STUDY LIMITATIONS. One limitation of the present
study is its protocol-determined moderate size.
Therefore, the extremely low MACCE rate in this
ﬁrst multicenter trial may require further conﬁrma-
tion in large-size clinical studies or registries that
will be adequately powered for clinical endpoints.
Another limitation is that selection of the embolic
protection device was left to the operator’s discre-
tion and was not standardized. Nevertheless, this
ﬁrst study fully describes the feasibility of a novel
mesh-covered carotid stent implantation in an all-
comer CAS population in a multicenter setting.
Importantly, the 0% MACCE rate at 30 days is fully
consistent with the DW-MRI–determined low inci-
dence of new ischemic lesions and the extremely
low periprocedural lesion volume that is unprece-
dented by DW-MRI data in studies that employed
previous generations of carotid stents with embolic
ﬁlter protection.
STUDY IMPLICATIONS. This ﬁrst completed multi-
center study of a mesh-covered carotid stent in-
dicates that the use of CGuard system may translate
into minimized brain embolization during the CAS
procedure as well as during the stent healing period;
both may lead to a paradigm shift in CAS.
CONCLUSIONS
The use of the CGuard system in patients undergoing
CAS is feasible in a multicenter setting. In addition,
the beneﬁt of using CGuard may extend to the stent
healing period.
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PERSPECTIVES
WHAT IS KNOWN? CAS is associated with a stroke risk
mainly due to dislodgement of debris from the target
lesion during the procedure and during the healing
period.
WHAT IS NEW? We demonstrate the feasibility and
safety of the CGuard Embolic Protection Stent to
minimized cerebral embolization during CAS.
WHAT IS NEXT? The data have to be conﬁrmed in a
larger trial with clinical endpoints.
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